Rare DNA Mismatch Repair-Related Protein Loss in Patients with Intrahepatic Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma and Their Response to Immunotherapy.

Cancer Management and Research
Jing YuHongfeng Gou

Abstract

The patients with advanced mismatch repair deficiency (dMMR) cancers can benefit from programmed cell death 1 (PD-1) pathway blockade, regardless of the tumor type. Little is known about the prevalence of dMMR in intrahepatic cholangiocarcinoma (ICC) and combined hepatocellular-cholangiocarcinoma (cHCC-CC). This study aimed to assess the mismatch repair (MMR)-related protein expression in patients with ICC and cHCC-CC. Formalin-fixed, paraffin-embedded tumor specimens were obtained from patients undergoing surgery at the West china Hospital between 2009 and 2017. The immunoreactions for MLH1, MSH2, MSH6, and PMS2 were investigated to determine the MMR status. A total of 97 patients were evaluated, including 73 ICC patients and 24 cHCC-CC patients. The prevalence of dMMR was only found in two cases of 97 patients (2.06%). Both patients are ICC. In 24 cHCC-CC patients, no dMMR was observed. They did not receive an adjuvant chemotherapy after surgery. At the end of the follow-up, one patient was in a tumor-free state, and the other patient had local recurrence and metastasis. After receiving sintilimumab (an immune checkpoint inhibitor [ICI] for PD- 1), the patient had a partial response. DMMR was detected in few patients with ICC...Continue Reading

References

Feb 27, 2001·Journal of Surgical Oncology·T SutoS Nakamura
May 27, 2003·Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B·Fausto SessaCarlo Capella
Jun 29, 2004·Virchows Archiv : an International Journal of Pathology·Angelica A SaettaEfstratios Patsouris
Jan 22, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S PopatR S Houlston
Apr 9, 2008·Gastroenterology·Yvette SchwitalleMagnus von Knebel Doeberitz
Apr 10, 2008·International Journal of Cancer. Journal International Du Cancer·Patrice WatsonHenry T Lynch
Apr 28, 2010·Gastroenterology·C Richard Boland, Ajay Goel
Aug 28, 2010·Journal of Gastroenterology and Hepatology·Matthew M Yeh
Apr 3, 2013·Cold Spring Harbor Perspectives in Biology·Josef Jiricny
Mar 4, 2014·Lancet·Nataliya Razumilava, Gregory J Gores
Mar 4, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J GoldsteinM J Overman
Oct 14, 2014·Journal of Gynecologic Oncology·Masafumi KatoKenichi Furuya
Jun 2, 2015·The New England Journal of Medicine·Dung T LeLuis A Diaz
Nov 1, 2016·Nature Medicine·Ronald J HauseStephen J Salipante
Nov 11, 2016·Chinese Clinical Oncology·Vitor Werneck Krauss SilvaJinru Shia
Jun 18, 2017·Cold Spring Harbor Molecular Case Studies·Elena CzinkChristoph Springfeld
Mar 1, 2016·Trends in Cancer·Matthias Kloor, Magnus von Knebel Doeberitz
Feb 23, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Leigh MarcusRichard Pazdur
Mar 10, 2019·Liver International : Official Journal of the International Association for the Study of the Liver·Shahid A KhanGiovanni Brandi
Mar 27, 2019·Journal of Hepatology·Paola BertuccioEva Negri
May 3, 2020·International Journal of Cancer. Journal International Du Cancer·Sarina A Piha-PaulToshihiko Doi
Jun 25, 2020·ESMO Open·Gilbert SpizzoAndreas Seeber

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.

© 2021 Meta ULC. All rights reserved